Results 311 to 320 of about 44,321 (338)

Bispecific antibodies rise again

Nature Reviews Drug Discovery, 2014
Amgen's blinatumomab is setting the stage for a bispecific revival, enabled by new formats that may solve the field's long-standing problems.
openaire   +2 more sources

Bispecific antibodies.

Critical reviews in immunology, 1993
Bispecific antibodies--molecules combining two different antigenic specificities--are currently being developed as new agents for immunotherapy and for basic studies in cell biology. Bispecific antibodies (BsAb) are prepared by chemically linking two different monoclonal antibodies or by fusing two hybridoma cell lines to produce a hybrid-hybridoma ...
M W, Fanger, P M, Morganelli, P M, Guyre
openaire   +1 more source

Catumaxomab: A bispecific trifunctional antibody

Drugs of Today, 2009
The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells.
M, Sebastian, A, Kuemmel, M, Schmidt, A, Schmittel   +3 more
openaire   +2 more sources

A revival of bispecific antibodies

Trends in Biotechnology, 2004
Bispecific antibodies usually do not occur in nature but are constructed by recombinant DNA or cell-fusion technologies. Most are designed to recruit cytotoxic effector cells of the immune system effectively against pathogenic target cells. This complex task explains why, after more than 15 years of extensive research, many different formats of ...
Peter, Kufer, Ralf, Lutterbüse, Patrick A, Baeuerle   +2 more
openaire   +2 more sources

Chemical Production of Bispecific Antibodies

2004
This chapter discusses two related methods for creating Fab' x Fab' chemically linked BsAb. Both methods require the generation of purified F(ab')2 fragments of each antibody and use reagents that react with the free thiols generated upon reduction of interheavy chain disulfide bonds of the F(ab')2 fragments. Upon reduction, the resulting Fabs are then
Robert F, Graziano, Paul, Guptill
openaire   +2 more sources

Bispecific antibody therapy for lymphoma

Best Practice & Research Clinical Haematology
The rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL.
Genevieve M, Gerhard, Gottfried, von Keudell   +1 more
openaire   +2 more sources

Bispecific antibodies in cancer therapy

Current Opinion in Immunology, 1999
Based upon in vitro and animal studies, a number of Phase I and II clinical trials have been initiated to test whether bispecific antibodies could redirect immune effectors against tumor cells in cancer patients. Recently, results from those trials showed beneficial effects in some patients but it is clear many problems remain to be solved. In addition,
D M, Segal, G J, Weiner, L M, Weiner
openaire   +2 more sources

Introduction: bispecific antibodies

Journal of Immunological Methods, 2001
D M, Segal, G J, Weiner, L M, Weiner
openaire   +2 more sources

Bispecific antibodies in oncology

Nature Reviews Drug Discovery, 2022
Arman, Esfandiari, Sorcha, Cassidy, Rachel M, Webster   +2 more
openaire   +2 more sources

Bispecific Antibody Therapy in Hemophilia

New England Journal of Medicine, 2017
Hemophilia A is the most common severe inherited bleeding disorder in humans. Bleeding occurs as a result of a deficiency or dysfunction of the procoagulant cofactor protein, factor VIII. For the past 50 years, the treatment and prevention of bleeding in hemophilia A has involved the intravenous infusion of plasma-derived or recombinant factor VIII ...
openaire   +2 more sources